Education
About Us
Working with TipRanks
Follow Us
Apollomics (APLM)
NASDAQ:APLM
APLM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.66 - $36.05
Previous CloseN/A
Volume6.18K
Average Volume (3M)29.76K
Market Cap
$5.69M
Enterprise Value$1.95M
Total Cash (Recent Filing)$25.93M
Total Debt (Recent Filing)$4.72M
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Sep 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.91
Shares Outstanding1,103,348
10 Day Avg. Volume53,344
30 Day Avg. Volume29,761
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue0.86
Enterprise Value/Gross Profit0.86
Enterprise Value/Ebitda-0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Apollomics News
APLM FAQ
What was Apollomics’s price range in the past 12 months?
Apollomics lowest stock price was $3.66 and its highest was $36.05 in the past 12 months.
What is Apollomics’s market cap?
Apollomics’s market cap is $5.69M.
When is Apollomics’s upcoming earnings report date?
Apollomics’s upcoming earnings report date is Sep 25, 2025 which is in 17 days.
How were Apollomics’s earnings last quarter?
Apollomics released its earnings results on Apr 03, 2025. The company reported -$16.913 earnings per share for the quarter, missing the consensus estimate of N/A by -$16.913.
Is Apollomics overvalued?
According to Wall Street analysts Apollomics’s price is currently Overvalued.
Does Apollomics pay dividends?
Apollomics does not currently pay dividends.
What is Apollomics’s EPS estimate?
Apollomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apollomics have?
Apollomics has 1,103,348 shares outstanding.
What happened to Apollomics’s price movement after its last earnings report?
Apollomics reported an EPS of -$16.913 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.581%.
Which hedge fund is a major shareholder of Apollomics?
Currently, no hedge funds are holding shares in APLM
Company Description
Apollomics
Apollomics, Inc. (APLM) is a biopharmaceutical company focused on the discovery and development of novel oncology therapies. The company operates in the healthcare sector, specifically targeting the treatment of cancers through innovative drug development. Apollomics' core products include a pipeline of small-molecule and biologic drug candidates designed to address unmet medical needs in oncology.
Technical Analysis
Soligenix
―
MetaVia
―
TransCode Therapeutics
―
Silexion Therapeutics
―
Lipella Pharmaceuticals, Inc.
―
Ownership Overview
―
Insiders
0.04% Mutual Funds
― Other Institutional Investors
99.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---